<p>SAN DIEGO ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk <a href="https://www.mdanderson.org/cancer-types/myeloproliferative-neoplasm.html">myelofibrosis</a><u>, a rare bone marrow cancer, </u>according to results of the Phase III TRANSFORM-1 trial reported by researchers from <a href="https://www.mdanderson.org/">The University of Texas MD Anderson Cancer Center</a>.</p>